TrialNature medicine2023

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Ari VanderWalde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.